[ASAP] An Investigation into the In Vitro Targeted Killing of CD44-Expressing Triple-Negative Breast Cancer Cells Using Recombinant Photoimmunotherapeutics Compared to Auristatin-F-Based Antibody-Drug Conjugates

AI Summary

This article focuses on comparing the efficacy of recombinant photoimmunotherapeutics against CD44-expressing triple-negative breast cancer cells with traditional antibody-drug conjugates using Auristatin-F. The study aims to investigate the targeted killing of cancer cells in vitro. The research may provide insights into potential new treatment strategies for triple-negative breast cancer.